Abstract
Overweight, obesity and the metabolic syndrome occur in genetically susceptible individuals with environmental influences, and may be further compounded by other disorders of metabolism or pharmacological therapy that increase insulin resistance or promotes weight gain. Treatment of the metabolic syndrome should focus on treatment of each individual component first. Lifestyle modification, including diet and exercise with a goal of weight reduction, is the foundation of any successful treatment regimen for the metabolic syndrome. Pharmacological therapy should be individualized and targeted to normalize blood pressure, HDL cholesterol, triglycerides and glucose values. If successful, comprehensive management of the metabolic syndrome promises to delay or prevent the development of coronary heart disease and Type 2 diabetes mellitus.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2059-2075 |
| Number of pages | 17 |
| Journal | Expert Opinion on Pharmacotherapy |
| Volume | 8 |
| Issue number | 13 |
| DOIs | |
| State | Published - Sep 2007 |
Funding
Metformin is considered a strong first-line choice for obese diabetic patients. This is supported by the data from the UKPDS (UK Prospective Diabetes Study). In this landmark study, metformin therapy achieved a reduction in the risk of CHD and decrease in total mortality in a subgroup of overweight subjects [46]. The UKPDS data further emphasized the value of reducing hemoglobinA 1c – a proven risk factor for vascular disease in diabetics [47].
Keywords
- Coronary artery disease
- Coronary prevention
- Coronary risk
- Dyslipidemia
- Glucose intolerance
- Hypertension
- Insulin resistance
- Metabolic syndrome
- Obesity
- T2DM
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology
